68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Phase 1 Terminated 42 enrolled University of Lausanne Hospitals George Coukos, MD PhD, Head of oncology · collab

NaSingle-groupOpen-labelDiagnostic

Summary

This study will assess the potential of the 68Ga-NODAGA-RGD for the evaluation of neoangiogenesis in patients followed for a neoplastic pathology and for whom a18F-FDG (or 18F-FET for gliomas) is indicated for initial extension evaluation or suspicion of recurrent tumor.

Timeline

Start: 2014-03
Primary completion: 2023-08
Completion: 2023-09

Outcome

Outcome not reported

Stopped: “lack of resources”

Publications

Results Durante S, Dunet V, Gorostidi F, Mitsakis P, Schaefer N, Delage J, Prior JO. Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study. EJNMMI Res. 2020 May 7;10(1):47. doi: 10.1186/s13550-020-00638-w.
Dietz M, Dunet V, Mantziari S, Pomoni A, Dias Correia R, Testart Dardel N, Boughdad S, Nicod Lalonde M, Treglia G, Schafer M, Schaefer N, Prior JO. Comparison of integrin alphavbeta3 expression with 68Ga-NODAGA-RGD PET/CT and glucose metabolism with 18F-FDG PET/CT in esophageal or gastroesophageal junction cancers. Eur J Hybrid Imaging. 2023 Feb 1;7(1):3. doi: 10.1186/s41824-023-00162-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	68Ga-NODAGA-RGD	Diagnostic / imaging agent	200 mbq	Intravenous

Indications

No indication recorded.